next-generation sequencing in APAC

The fastest-growing areas for APAC’s next-generation sequencing market

The next-generation sequencing (NGS) market is expected to be APAC’s fastest-growing in-vitro diagnostics segment between now and 2025. More healthcare providers are recognising the significant advantages of this technology for prenatal testing and cancer diagnosis, which is driving widespread NGS adoption in the region and creating opportunities for IVD company growth. 

We estimate that APAC’s NGS instrument and testing markets will grow at a compound annual growth rate (CAGR) of between 14 and 15% between 2022 and 2025. Explore our key forecasts to stay ahead of market changes and inform your mid-term strategy.

Key forecasts for 2022‒2025

  • Next-generation sequencing is expected to be the fastest-growing IVD market segment in most APAC countries including China, Japan and South Korea
  • The sequencing instrument market is expected to grow fastest in countries such as China and South Korea due to the rapid pace of NGS adoption. Demand for new instruments is expected to be moderate in Australia and Vietnam as laboratories will still be able to meet the rising demand for NGS tests on their current installed base of instruments
  • The sample-preparation instruments and reagents market is expected to grow in line with the overall growth of NGS, with a growing preference for automated sample preparation
  • Non-invasive prenatal testing (NIPT) makes up a large proportion of the NGS market and will continue to experience strong growth due to increasing awareness of NIPT’s advantages as an alternative to invasive testing 
  • Oncology testing will experience strong growth as a result of rising cancer incidence in the region and growing reimbursement for NGS oncology tests in key markets. Recent reimbursement approvals for multiplex gene assays in Japan signal a new era for the country’s use of NGS testing
  • Genetic testing remains a comparatively slow-growing NGS test segment, with low uptake of genetic screening in the general population 
  • Infectious diseases testing makes up a relatively small proportion of NGS tests in the region. In Indonesia, there is a growing use of NGS testing to screen for sexually transmitted diseases. However, the use of NGS testing for the diagnosis of infectious diseases is minimal in several of the region’s developed markets including Japan and South Korea

Growing Your NGS Business in APAC

As the region’s NGS market continues to evolve, Clearstate’s IVD Gateway data solution can help you identify opportunities for your organisation. Understand where and how to gain market share with insights to support your strategic and practical business planning. 

IVD Gateway Size and Share Plus tracks market size, share and growth in 38 countries annually. The latest data and forecasts for APAC will be available in April 2022.

Find out more about IVD Gateway and how it can help your business.